Lab
Genesis Diagnostic Services INC
Genesis Diagnostic Services INC was paid $23K by Medicaid between Dec 2021 and Apr 2024, across 8 billing codes. Its largest line is 87635, Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe — 39% of everything it billed.
33Billing provider infoGENESIS DIAGNOSTIC SERVICES INC
FARMERS BRANCH, TX 75234
FARMERS BRANCH, TX 75234
33aNPI1326694670assigned 08/13/2019
33bProvider typeClinical Medical Laboratory
28Total paid$23K
24GClaims7,680
24DCodes billed8
24AFirst – last monthDec 2021 – Apr 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#211 of 436
Median peer was paid$17K
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 47 | $0.00 | |
| 2022 | 3,496 | $5K | |
| 2023 | 3,700 | $12K | |
| 2024incomplete | 437 | $7K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 39% | 1,175 | 1,087 | $9K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 32% | 1,924 | 1,735 | $8K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 13% | 2,277 | 1,941 | $3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 11% | 1,924 | 1,735 | $3K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 4.4% | 286 | 170 | $1K |
| 36415 | Collection of venous blood by venipuncture | 0% | 14 | 12 | $0.00 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 0% | 14 | 12 | $0.00 |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 0% | 66 | 66 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNAVEED, SYED (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| National Clinical Labs | Lisle, IL | $6.17M |
| Texas Physicians Primary Care, PLLC | Mesquite, TX | $4.83M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.